Jesus Gomez Navarro, MD
Ixazomib (Ninlaro) improved progression-free survival (PFS) compared with placebo as a maintenance therapy in adult patients with multiple myeloma who responded to high-dose therapy (HDT) and autologous stem cell transplant (ASCT), according to topline findings from the phase III TOURMALINE-MM3 study.
Takeda Pharmaceutical Company, the manufacturer of the proteasome inhibitor, did not provide any specific from the trial, but plans to submit the results for presentations at the 2018 ASH Annual Meeting in December.
“Within the maintenance setting, it is critical that we find agents that are efficacious, tolerable and convenient,” Jesús Gomez Navarro, MD, Vice President, Head of Oncology Clinical Research and Development, Takeda.
... to read the full story